INTRODUCTION
H OW DRUG DISCOVERY EFFORTS are managed within highthroughput screening (HTS) laboratories worldwide varies, with different approaches, tools, and strategies being applied. Because a significant number of HTS laboratories have been in existence for 8 to 10 years, many in the industry are disappointed that few drug candidates, originally screened in HTS, have made it to the market. However, it has been a steep learning curve. Only in the past few years have HTS scientists been able to bring together sophisticated automated equipment, robust assays, validated targets, high-quality compound libraries, useful data analysis tools, and a better understanding of how to use HTS within the whole of drug discovery. HTS is beginning to show its strength.
A recent worldwide study involving 51 HTS directors reporting for 53 laboratories and 39 suppliers, High Throughput Screening: Improving Strategies, Technologies, and Productivity, 1 documents current HTS successes. Altogether, 74 clinical candidates, leads originally found in HTS laboratories, were reported by the HTS directors participating in the study. Two of these products are on the market. The material in this article is based on this 850-page industry report published in December 2003.
FINE-TUNING HTS STRATEGIES FOR DRUG DISCOVERY
HTS directors are making a concerted effort to improve the quality of the targets, the assays, the screening process, and compound libraries. For many HTS laboratories, a push for quantity and higher throughput in the past has changed to a push for higher quality data that provide more information and quality leads. Armed with better compound libraries, more experience with their libraries and targets, and virtual screening tools, many HTS directors are screening focused libraries. One-third of the respondents in the new study use virtual screening to help them generate focused libraries.
The industrialization of the HTS laboratory is also evolving, and use of automation, miniaturization, and higher throughputs is expected to steadily increase. Average throughput numbers, reported as the number of wells read per week, have continually increased since our HTS studies began in 1998. Five HTS directors in this study, about 10% of those interviewed, expect to be reading 1 million or more wells per week by 2005.
The average number of targets screened at individual HTS laboratories, 17 in 2003, is expected to grow to 20 targets by 2005. G protein-coupled receptors (GPCRs) represent the largest target class screened, with an average of almost 31% of all screens for HTS laboratories participating in this study. The percentage of GPCR targets is expected to grow to more than 33% by 2005. Kinases are the second most popular target type, with 18% use overall in 2003.
Most notable in the push for higher quality data is an increasing use of cell-based assays in high-throughput mode. By 2005, for the first time, HTS directors in this study predict that cell-based assays will represent more than half of the assays they use on average. Cell-based assays can provide functional read-outs, as well as permeability and cytotoxicity information, and they provide a better prediction of how the compound will behave in the cellular environment. Currently, the cell-based assays used most often are second-messenger, ion channel flux, and reporter gene assays. Increased use is expected of second-messenger, translocation, antisense/RNAi, ion channel voltage, and cell motility assays.
For biochemical assays, the assays used most often are direct enzyme activity and receptor-binding assays, and a slight increase in second-messenger assays is expected. Biochemical assays made up the majority of assays in 2003, and volumes used (wells screened per week) will also increase by 2005 alongside cell-based assays, although at a slower pace.
The 384-well microplate format was the dominant format for HTS in 2003 and will continue to be in 2005, although the use of low-volume 384-well microplates will show the most growth. Use of 1536-well microplates will also continue to grow.
SUCCESSES REPORTED
As a measure of success to date, participants were asked to report on the percentage of targets that generated leads in 2002. Because it requires at least 1 year to determine whether a hit has become a lead, respondents were asked to report for 2002. Definitions of leads vary widely, so participants were asked to respond using a common definition to obtain comparable data. The definition used in this study is as follows:
A "lead" is defined as a hit confirmed by more than 1 assay in vitro and, if possible, in vivo, in a manner that shows biologically relevant activity that correlates to the target. To be a lead, the compound must show evidence that a structure activity relationship (SAR) can be built around it.
Of the HTS directors, 42 reported on the percentage of their targets that have generated leads. The large range of answers, from 8% to 100%, indicates the variation in the HTS laboratories, the types of targets, the challenges, and the processes. The results are shown in Figure 1 . Interestingly, the average percentages in the 2000 study and the 2002 study are almost identical, 44% and 43%, respectively, but in the new 2003 study, the percentage has jumped to 56%. It appears that the HTS laboratories are increasing their productivity overall.
Altogether, 38 laboratories report that they generated 662 leads in 2002, more than double the number as reported in the previous HTS study (326). The maximum from any one laboratory is 150, whereas the minimum is 1, as shown in Table 1 . In this count, most HTS directors included all leads in a series of leads for 1 target. In fact, several directors reported that they found multiple leads for almost all of their targets. The 1 respondent reporting having found 150 leads had 30 targets in 2002, with an average of 5 leads in a lead series for each.
In this study, as shown in Table 1 , HTS laboratories were sorted into two groups:
1. high-throughput group, reading 100,000 or more wells per week (27 HTS laboratories participating in this study); 2. medium-throughput group, reading fewer than 100,000 wells per week (26 HTS laboratories participating in this study).
A few comments from HTS directors regarding their success in finding leads follow. Although several directors said that it is either too early to evaluate successes from last year or that they have just set up their lead development group and successes have not yet materialized, many had a success story to relate This year we already found a lead that is not a "me too." We are quite efficient. I don't know what happened previously; there was not much screening before that, so it is hard to compare productivity levels. Successful screens produce multiple chemotypes per target, and the chemists start with about 2 and use the others as backup. The number I am providing here is the total. The ones actively being worked on at any given time might be about half of that.
HTS: Searching for Higher Productivity
For us, the hit-to-lead process has specific criteria. There are chemistry-type requirements: Lipinski rules, potency, selectivity, oral availability. That makes a lead. We are successful, highly successful actually, in kinases.
For 2 lead series that we generated in 2002, our success was probably related to the targets we selected.
The key to our success in finding 10 leads was having biology and chemistry working together on a focused target class. The next measure of success is the number of leads originally found through HTS methods that have actually been tested in humans. Of the HTS directors, 28 report having HTS leads in clinical trials for testing in humans. These 28 directors report a total of 74 drug candidates originally found in HTS laboratories as follows:
• 37 drug candidates from 14 high-throughput laboratories, • 37 drug candidates from 14 medium-throughput laboratories.
The 74 drug candidates generated by HTS laboratories are listed in Table 2 and shown by date originally screened in Figure 2 . This number is up compared to the 2000 study, in which 18 respondents reported 46 drug candidates from HTS; in the 2002 study, 23 respondents reported 62 drug candidates from HTS. The largest number of drug candidates from any 1 laboratory is 7.
Based on the reporting HTS directors' responses, 2 nuclear receptors originally screened in a medium-throughput setting in 1989 have reached the market. Both compounds were identified using cell-based transient transfection assays wherein an expression plasmid for the nuclear receptor is cotransfected with a luciferase reporter plasmid containing a receptor-specific hormoneresponsive promoter. The assays were formatted for high throughput (96-well microplates), and automation was used to perform the experiments.
These 2 commercial products were identified and developed, and they are marketed in the United States as Panretin ® and Targretin® by Ligand Pharmaceuticals, Inc. Panretin ® , also known as 9-cis retinoic acid, is a ligand for both retinoic acid receptors (RARs) and retinoid X receptors (RXRs), both of which are nuclear receptors. Panretin® has been approved for the treatment of Kaposi's sarcoma. Targretin®, also known as Bexarotene or LGD1069, is a synthetic RXR-selective ligand. Targretin® has been approved for the treatment of cutaneous T cell lymphoma and is currently in Phase III trials for the treatment of non-small cell lung cancer.
IMPROVING PRODUCTIVITY
To understand how HTS directors are improving productivity, they were asked to explain what changes they made in 2003 to increase their success in lead finding, along with what strategies they expected to use to increase productivity moving forward.
The answers provided indicate a maturing industry with a sophisticated use of tools, resources, and past experience. To increase productivity, most companies are • increasing the information and quality of data on leads passed on to lead optimization; • industrializing and streamlining their HTS laboratories; and • increasing the communication and integration of the HTS laboratory with other internal drug discovery groups.
Most HTS directors describe a multipronged strategy to improve lead finding and the success of HTS in drug discovery, which involves everything from the organization of drug discovery groups to sophisticated instrumentation and a growing expertise in identifying targets, robust assays, quality compound libraries, and quality leads. With such complexity, a summary list can only outline the overall strategies being employed to increase productivity. A summary of strategic components is shown in Table 3 , but the comments from HTS directors indicate how these components are combined to form a successful strategy:
To increase productivity, we have adopted a process group concept and an industrialized screening approach. We have increased the size of our compound deck and have added additional information beyond what you get in the primary screen. We expect further improvements on all accounts.
Our success is based on target and type of assay, compound collection, and the timing of our screening (as this relates to the competitive landscape; if we screen a particular type of target before it becomes popular, then we gain an advantage). We're trying to evaluate the compound collection and selection process to eliminate bad compounds (commonly interfering, toxic, etc.) and enrich it in good compounds. We're also looking to improve in-line screening. We try to get a chemist to look at every single potential lead to evaluate it before we invest more effort.
We improved our productivity through a complete analysis of our drug discovery process. We have remodeled our internal communication and focused on improving assay development. We brought in biochemists and biophysicists to work on developing better biochemical and cell-based screens. We also automated and integrated sample and compound management. We are increasing our sophistication and information management of confirmed hits from our screens to answer questions downstream. We hope to shorten cycle time.
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Strategic Components Number of Mentions
Expanding and improving compound libraries 24 Improving target validation 17 Increasing the amount of quality information obtained from screening 15 Miniaturizing, streamlining, and industrializing the high-throughput screening laboratory 11 Working more closely with other internal drug discovery groups 11 Providing more follow-up testing and ADME/Tox earlier in the drug discovery process 9 Improving data management and information technology systems 9 Increasing assay reliability and robustness 5 Developing focused libraries 5 of lead candidates as they are handed on to lead optimization (chemistry) might help. We are focused on improving quality, not on increasing the numbers screened.
High-quality data, using the best assay for the target, high-quality compounds, good target choice, and target validation lead to improved productivity.
HTS laboratories are using various approaches to increase productivity. Both medium-and high-throughput laboratories have produced leads and drug candidates, and a surprising number of leads have come from newer HTS laboratories. Increases in productivity stem from a combination of improvements in the organization and integration of the HTS laboratory with other internal drug discovery groups, more efficient automated equipment and higher throughput, more robust assays and cell-based assays, better validated targets, improved data analysis tools, larger compound libraries as well as focused compound libraries, and a better understanding of how to use HTS within the whole of drug discovery. Increasing numbers of leads and drug candidates are being found for even the more difficult targets.
Year to year, HTS has become progressively more successful as a drug discovery tool.
